Amneal Pharmaceuticals Inc. | Mid-cap | Healthcare
$9.97
-3.11%
| Amneal Stock Comparison:
Amneal vs ZoetisAmneal vs Haleon Plc - ADRAmneal vs Regencell BioscienceAmneal vs Alkermes plcAmneal vs Prestige ConsumerAmneal vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 695.4M
Gross Profit 255.9M 36.80%
Operating Income 100.9M 14.51%
Net Income 24.6M 3.54%
EPS (Diluted) $0.04

Balance Sheet Metrics

Total Assets 3.4B
Total Liabilities 3.4B
Shareholders Equity -59.4M

Cash Flow Metrics

Operating Cash Flow -11.0M
Free Cash Flow -10.9M

Revenue & Profitability Trend

Amneal Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 2.8B 2.4B 2.2B 2.1B 2.0B
Cost of Goods Sold i 1.8B 1.6B 1.4B 1.3B 1.4B
Gross Profit i 1.0B 820.6M 784.7M 769.0M 628.4M
Gross Margin % i 36.5% 34.3% 35.5% 36.7% 31.5%
Operating Expenses
Research & Development i 196.6M 167.8M 200.0M 209.6M 190.6M
Selling, General & Administrative i 476.4M 429.7M 399.7M 365.5M 326.7M
Other Operating Expenses i - -1.1M -4.0M - -
Total Operating Expenses i 673.0M 596.3M 595.8M 575.1M 517.3M
Operating Income i 347.4M 224.2M 188.9M 193.9M 111.1M
Operating Margin % i 12.4% 9.4% 8.5% 9.3% 5.6%
Non-Operating Items
Interest Income i - - - - -
Interest Expense i 258.6M 210.6M 158.4M 136.3M 146.0M
Other Non-Operating Income -143.9M -13.1M -278.4M -26.2M -863.0K
Pre-tax Income i -55.0M -40.3M -248.1M 31.4M -35.8M
Income Tax i 18.9M 8.5M 6.7M 11.2M -104.4M
Effective Tax Rate % i 0.0% 0.0% 0.0% 35.7% 0.0%
Net Income i -73.9M -48.7M -254.8M 20.2M 68.6M
Net Margin % i -2.6% -2.0% -11.5% 1.0% 3.4%
Key Metrics
EBITDA i 595.4M 418.0M 446.6M 442.6M 349.1M
EPS (Basic) i $-0.38 $-0.48 $-0.86 $0.07 $0.62
EPS (Diluted) i $-0.38 $-0.48 $-0.86 $0.07 $0.61
Basic Shares Outstanding i 308978000 176136000 150944000 148922000 147443000
Diluted Shares Outstanding i 308978000 176136000 150944000 148922000 147443000

Income Statement Trend

Amneal Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 110.6M 91.5M 26.0M 247.8M 341.4M
Short-term Investments i - - - - -
Accounts Receivable i 775.7M 613.7M 741.8M 662.6M 638.9M
Inventory i 612.5M 581.4M 530.7M 489.4M 490.6M
Other Current Assets - - - - -
Total Current Assets i 1.6B 1.4B 1.4B 1.5B 1.6B
Non-Current Assets
Property, Plant & Equipment i 98.8M 102.6M 119.5M 124.8M 127.0M
Goodwill i 1.9B 2.1B 2.3B 2.4B 2.4B
Intangible Assets i 732.4M 890.4M 1.1B 1.2B 1.3B
Long-term Investments 35.9M 37.1M 85.6M 0 0
Other Non-Current Assets 8.1M 11.6M 10.4M 10.8M 9.5M
Total Non-Current Assets i 1.9B 2.1B 2.4B 2.4B 2.5B
Total Assets i 3.5B 3.5B 3.8B 3.9B 4.0B
Liabilities
Current Liabilities
Accounts Payable i 258.7M 143.6M 166.0M 131.1M 153.1M
Short-term Debt i 340.3M 227.6M 104.6M 46.0M 57.5M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 31.8M 77.0M 107.5M 58.0M -
Total Current Liabilities i 1.1B 846.6M 752.8M 677.2M 676.9M
Non-Current Liabilities
Long-term Debt i 2.3B 2.5B 2.7B 2.8B 2.9B
Deferred Tax Liabilities i - - - - -
Other Non-Current Liabilities 94.1M 8.2M 70.2M 2.7M 5.9M
Total Non-Current Liabilities i 2.5B 2.6B 2.9B 2.9B 3.0B
Total Liabilities i 3.6B 3.5B 3.6B 3.6B 3.7B
Equity
Common Stock i 3.1M 3.1M 3.0M 3.0M 3.0M
Retained Earnings i -607.1M -490.2M -406.2M -276.2M -286.8M
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i -109.5M 20.0M 184.0M 367.0M 344.9M
Key Metrics
Total Debt i 2.6B 2.8B 2.8B 2.9B 2.9B
Working Capital i 458.0M 531.3M 659.0M 842.9M 874.6M

Balance Sheet Composition

Amneal Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i -73.9M -48.7M -254.8M 20.2M 68.6M
Depreciation & Amortization i 236.2M 229.4M 240.2M 233.4M 235.4M
Stock-Based Compensation i 27.8M 26.8M 31.8M 28.4M 20.8M
Working Capital Changes i -57.6M -94.8M -71.9M -109.3M -96.3M
Operating Cash Flow i 136.9M 157.1M -37.2M 187.9M 248.4M
Investing Activities
Capital Expenditures i -60.3M -46.8M -48.8M -50.9M -61.8M
Acquisitions i 12.0M 0 -84.7M -146.5M -251.4M
Investment Purchases i - - - - -
Investment Sales i - - - - -
Investing Cash Flow i -48.3M -46.8M -132.5M -192.5M -313.2M
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i - - - - -
Debt Issuance i 0 217.7M 0 0 180.0M
Debt Repayment i -233.1M -414.1M -123.3M -79.2M -37.0M
Financing Cash Flow i -212.9M -213.0M -107.3M -139.0M 131.5M
Free Cash Flow i 220.1M 276.4M -25.5M 189.2M 312.8M
Net Change in Cash i -124.3M -102.7M -277.0M -143.5M 66.7M

Cash Flow Trend

Amneal Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 1,036.00
Forward P/E 14.59
Price to Book -29.23
Price to Sales 1.14
PEG Ratio 4.14

Profitability Ratios

Profit Margin 0.12%
Operating Margin 15.46%
Return on Equity 106.73%
Return on Assets 6.85%

Financial Health

Current Ratio 1.43
Debt to Equity -22.94
Beta 1.18

Per Share Data

EPS (TTM) $0.01
Book Value per Share $-0.36
Revenue per Share $9.17

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
amrx 3.3B 1,036.00 -29.23 106.73% 0.12% -22.94
Zoetis 65.1B 25.16 13.06 52.77% 27.83% 137.01
Haleon Plc - ADR 41.9B 20.09 5.12 9.38% 13.81% 53.41
Regencell Bioscience 9.6B -2,233.99 1,328.57 -47.77% 0.00% 0.00
Alkermes plc 5.1B 14.95 3.14 23.94% 23.15% 4.47
Prestige Consumer 3.8B 17.92 2.07 12.30% 18.86% 56.91

Financial data is updated regularly. All figures are in the company's reporting currency.